Real World Evidence Undercuts Value Of Hereditary Angioedema Drugs In ICER Analysis Update

 
• By Cathy Kelly

But results of the re-analysis of three HAE treatments aren’t necessarily expected to be typical for RWE-based updates undertaken in the future by the Institute for Clinical and Economic Review.

Does RWE offer a more accurate view of drug benefit and risk? • Source: Alamy

More from Real-World Evidence

More from Clinical Trials